fashion -WSS

fashion

author：fashion 2025-09-29 21:29:12 - browse：7553

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Gene therapy denied for Afghan refugee whose father aided U.S.

WSS

Ohioans vote in high

Boston Scientific acquires urology company Axonics for $3.7 billion

Hospital chaplains balance Covid safety with patients’ spiritual needs

Former Georgia lieutenant governor says he received grand jury subpoena

The painfully weak evidence on taking collagen to treat arthritis

Profiling embryos to choose those with higher IQs is almost a reality

hotspot

fashion

hotspot

New air purifier tech could be key to improving indoor air quality

Nonprofit, backed by Microsoft, to certify AI tools in health care

The cancer drug shortage isn’t new — and neither are the solutions

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

BioMarin wins approval for gene therapy to treat hemophilia A

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hospital chaplains balance Covid safety with patients’ spiritual needs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

An Ebola outbreak presents a new mystery involving children

focus

Lessons Learned: This is why you network to find that industry job you want

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Biden praises World Series champion Astros for impact off the field during White House celebration

Gene therapy denied for Afghan refugee whose father aided U.S.

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Life science postdocs should get big pay hike, NIH panel says

hotspot

leisure time

focus

focus